NAM
IOVA icon

NorthCrest Asset Manangement’s Iovance Biotherapeutics IOVA Stock Holding History

NorthCrest Asset Manangement’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.9K Buy
+13,028
New +$49.5K ﹤0.01% 904

Other funds holding IOVA

MCP
Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CWM
Centurion Wealth Management Mclean, Virginia $418M AUM 23.14% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
TIA
Traphagen Investment Advisors Oradell, New Jersey $1.4B AUM 19.32% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

NorthCrest Asset Manangement's IOVA Position: Q2 2026 in Review

NorthCrest Asset Manangement opened a new position in Iovance Biotherapeutics (IOVA) in Q2 2026: 13,028 shares worth $56.9K. The stake represents ﹤0.01% of the portfolio and ranks #904 among its holdings.

18 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • NorthCrest Asset Manangement held 13,028 shares of Iovance Biotherapeutics worth $56.9K as of Q2 2026.
  • Iovance Biotherapeutics was a new NorthCrest Asset Manangement position in Q2 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of NorthCrest Asset Manangement's portfolio in Q2 2026, its #904 holding.
  • 18 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on NorthCrest Asset Manangement's 13F filing for Q2 2026, filed 15 Jul 2026.